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Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion
gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase
activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival,
but there are significant concerns about cardiovascular toxicity. Cardiovascular risk
can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy,
improvement of modifiable cardiovascular risk factors through lifestyle modifications,
and prescription of drugs for primary or secondary prevention. Which examinations are
necessary, and when do they have to be scheduled? How often should a TKI-treated
patient undergo which cardiology test or exam? Is there an accurate way to estimate
the risk that each TKI may determine a cardiovascular adverse event in a CML patient?
In a few words, how can we optimize the cardiovascular risk management in CML
patients before and during TKI treatment? The aim of this review is to describe cardiac
and vascular toxicity of TKIs used for CML treatment according to the most recent
literature and to identify unmet clinical needs in cardiovascular risk management and
complications in these patients. Regarding the TKI-induced cardiovascular toxicity, the
full mechanism is still unclear, but it is accepted that different factors may play different
roles: endothelial damage and atherosclerosis, metabolic impairment, hypertensive
effect, glomerular impairment, and mast-cell disruption. Preventive strategies are aimed
at minimizing cardiovascular risk when CML is diagnosed. Cardio-oncology units
in specialized hematology centers may afford a personalized and multidisciplinary
approach to the patient, optimizing the balance between treatment of the neoplasm
and management of cardiovascular risk.
Keywords: cardiovascular events, chronic myelocytic leukemia, cardiovascular risk, cardio-oncology, tyrosine
kinase inhibitions therapy
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene,
encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase (TK) activity. The
use of tyrosine kinase inhibitors (TKIs), since the appearance of the first-generation inhibitor
imatinib, in 2001, has dramatically changed the management of the disease, impacting prognosis
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to the point of obtaining survival data comparable to that
of the general population (Faderl et al., 1999; Druker et al.,
2001). Second- and third-generation TKIs (nilotinib, dasatinib,
bosutinib, and ponatinib) have been demonstrated to be faster
and even more effective than imatinib in reaching deep molecular
responses (Jabbour et al., 2015; Vener et al., 2020).
These striking results obtained by second and third generation
TKIs, however, usually come along with a heavier toxicity profile.
Among the various adverse events known to be associated
with TKI therapies, adverse cardiovascular events (CVAEs) are
relatively often reported in clinical trials and in real-life drug
surveillance programs (Li et al., 2015; Moslehi and Deininger,
2015; Douxfils et al., 2016; Moslehi, 2016). Moreover, clinical
trials have proved the possibility of interrupting TKI therapies in
defined cases to be safe and convenient in terms of cumulative
toxicity, even in those patients that may need to restart TKIs after
a temporary interruption (Mahon et al., 2010; Hochhaus et al.,
2016; Ross et al., 2018).
Even though it is nowadays fully accepted that exposure to
anti-CML TKIs confers an excess risk of CVAEs in the patient,
data on underlying mechanisms are still unclear and (more
important and impacting), it is still not well established an
effective preventive and treatment strategy.
Which examinations are necessary, and when do they have to
be scheduled? How often should a TKI-treated patient undergo
which cardiology test or exam? Is there an accurate way to
estimate the risk that each TKI may lead to a CVAE in a CML
patient? In a few words, how can we optimize the cardiovascular
risk management in CML patients before and during TKI
treatment?
A lot of risk scores, based on the evaluation of multiple
variables, were validated to estimate the risk of developing a CV
events in the general healthy population. Of note, some of these
scores were not targeted at evaluating important outcomes like
heart failure, stroke, or symptomatic peripheral artery disease
(Aghel et al., 2017).
The aim of this review is to describe cardiac and vascular
toxicity of TKIs used for CML treatment according to
the most recent literature and to identify unmet clinical
needs in cardiovascular risk management and complications
in these patients.
MECHANISMS OF CARDIOVASCULAR
DAMAGE THROUGH TK INHIBITION
The most commonly reported, though still not completely
understood, tumor–treatment-related cardiotoxicity is that
caused by anthracyclines (ANT). The known mechanism
of cardiac damage by ANT resides in the drug mechanism
of action itself, which results in reactive oxygen species
(ROS) and nitrogen species hyperproduction, leading to
calcium and iron homeostasis disruption, nuclear damage,
and myocyte dysfunction. On the other hand, the ANT-
mediated blockade of II-beta-topoisomerase can cause
mitochondria impairment in cardiomyocytes and thus elevate
their ROS damage susceptibility. The clinical presentation
is a kind of acquired cardiomyopathy, referred to as
“ANT-induced cardiomyopathy.”
Tyrosine kinase inhibitors-induced cardiovascular toxicity
seems to have other roots, and even if the full mechanism of
cardiovascular damage is still unclear, it is widely accepted that
various factors may play different roles:
• Endothelial damage and atherosclerosis: nilotinib was
demonstrated to inhibit human vascular endothelial and
microvascular endothelial cell proliferation and survival,
both in presence and absence of VEGF, and determining
an increase of caspase-3 and -7 (markers of apoptosis),
determining damage that partially resumes the one known
to be caused by VEGF-inhibiting TKIs (Galvano et al.,
2019). Moreover, nilotinib causes an increased expression
of ICAM-1, VCAM-1, and E-selectin as pro-atherogenic
surface molecules in endothelial cells in in vitro models.
Imatinib was instead not capable of determining these
endothelial alterations in the same study. A similar
mechanism of damage may be inductively postulated for
ponatinib, a potent VEGFR inhibitor. Human umbilical
venous endothelial cells were tested in vitro with the
five available TKIs, demonstrating how dasatinib and
ponatinib induced apoptosis and necrosis also at lower
concentrations than those used for the treatment of CML,
while imatinib, nilotinib, and bosutinib did not, even after
72 h of exposure to the drugs (Hadzijusufovic et al., 2017;
Haguet et al., 2020).
• Metabolic impairment: data from trials evidence that
second-generation TKI nilotinib often determines glucose
level elevations and sometimes triggers or worsens a
preexisting type 2 diabetes mellitus, through the blocking
of a post-insulin receptor pathway. In fact, ABL seems
to be involved in the insulin pathway signaling, and its
blocking by TKI may cause decreased insulin sensitivity
and the need for an excess of insulin secretion. Moreover,
exposition to nilotinib appears to decrease also adiponectin
concentrations, thus further impairing tissues insulin
sensitivity (Frasca et al., 2007; Genua et al., 2009).
• Hypertensive effect: Arterial hypertension in a common
adverse event during treatment with nilotinib and
ponatinib. Both of these drugs potently inhibit VEGFR
among the other TK. VEGF physiologically supports
nitric oxide (NO)-dependent arterial vasodilation and
upregulates NO production acting on the endothelial cells,
thus regulating the basal arterial tone and pressure levels.
VEGF and VEGFR inhibitors determine the blocking of
this mechanism and may cause hypertension (Ku et al.,
1993; Hood et al., 1998). Arterial hypertension may itself
act as a potential risk factor for other and more severe CV
events, such as myocardial infarction and stroke.
• Glomerular impairment: VEGF also plays a role in
the kidneys in cellular proliferation and homeostasis.
The inhibition of its pathway may lead to glomerular
dysfunction, determining or worsening preexisting
proteinuria and hypertension (Kappers et al., 2009;
Lankhorst et al., 2015; Li et al., 2015).
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• Mast-cell disruption: Mast cells have an important role
in vascular tissue repair, producing and releasing heparin
and other bioactive tissue plasminogen activators. Both
nilotinib and ponatinib have KIT-inhibiting activity and
thus may impair mast cell function. Imatinib has a KIT-
inhibiting activity as well, but it has been demonstrated
to be unable to impair endothelial cell regeneration and
to sensitize the endothelium to atherosclerosis generation,
suggesting that mast cell impairment alone is not sufficient
to determine a pro-atherogenic phenotype in endothelial
cells (Genua et al., 2009).
Indeed, the mechanisms involved are due either to the
inhibition of the main target of the molecules used to cure
CML (ABL inhibition, “on-target” effects) and of other kinases
that are not involved in the disease’s pathogenesis (“off-target”
effects; Force and Kolaja, 2011). However, it is a common idea
that off-target effects are more involved in the determination of
cardiovascular risk increase, in that first-generation TKI imatinib
appears even to be protective, improving the metabolic profile
of patients with diabetes and not affecting the age-adjusted
cardiovascular risk profile (Moslehi and Deininger, 2015).
Moreover, every TKI may have a different spectrum of
cardiac and/or vascular toxicity in different patients, according
to their age, sex, comorbidities, and the presence of additional
conventional and non-conventional cardiovascular risk factors
(i.e., smoking habits, dyslipidemia, overweight, familiarity,
diabetes, assumption of other therapies that may have CV toxicity
as known adverse events, and so on).
The conventional risk factors for CVAEs are traditionally
divided into modifiable and non-modifiable factors: respectively,
the first group includes dyslipidemia, hypertension, cigarette
smoking, obesity, and physical inactivity; the second group
includes age, sex, ethnicity, and family history. These risk
factors have been extensively proved to be significant in
a lot of population-based trials and on large-scale case–
control studies (Yusuf et al., 2004; D’Agostino et al., 2008).
Among the so-called non-conventional CV risk factors, high-
sensitivity C-reactive protein, interleukin-1 (IL-1), interleukin-
6 (IL-6), fibrinogen- and lipoprotein-associated phospholipase
A2, homocysteine, and lipoprotein (a) have been studied, and
elevation of the corresponding values appears to have a statistical
association with the occurrence of CVAEs in the general
population (Emerging Risk Factors Collaboration Kaptoge et al.,
2012).
The fact that CVAEs occur in CML patients while in
TKI therapy with preexisting (or upcoming) non-TKI-related
cardiovascular risk corroborates the hypothesis that primary
prevention is the key strategy in reducing the risk of developing
a CVAE for these patients. The most recent 2020 ELN
recommendations for CML diagnosis and treatment report
cardiovascular adverse events as the main non-hematologic
AEs and strongly recommend avoiding the choice of ponatinib
and nilotinib in patients with previous or concomitant arterial
vascular disease, even if the authors themselves add the
phrase “unless there is unique need” to the recommendation
(Hochhaus et al., 2020).
In 2016, Dorer et al. demonstrated how, after adjusting
covariates, there was a significant association between the
occurrence of cardiac failure and CVAEs and ponatinib dose
intensity in the PACE trial. In particular, the odds ratio (OR) for
cardiac failure was more than 2, for arterial thrombotic events
was more than 1.5, while for hypertension the OR was 1.3,
weaker but still significant. The strongest independent predictors
of arterial occlusive events were dose intensity, the history of an
ischemic disease, and advanced age (Dorer et al., 2016).
AVAILABLE TKIs AND RELATIVE CV
RISK PROFILE
In Table 1, the five available ABL-inhibiting TKIs were reports
along with the known cardiovascular toxicity profile and
mechanisms (see Table 1).
Imatinib
The first generation TKI imatinib is surely the most convenient
BCRABL-inhibiting drug in terms of cardiovascular and
metabolic toxicity. Imatinib therapy appears to be protective
against insulin resistance and hyperglycemia (Agostino et al.,
2011). In a large cohort of CML patients treated with imatinib
versus initial placebo, the imatinib group had lower rates
of peripheral arterial events (Giles et al., 2013). Preclinical
data suggest that imatinib may lower and reverse pulmonary
hypertension, so that the drug has been evaluated in several trials
for pulmonary hypertension treatment (Ghofrani et al., 2005).
Dasatinib
Vascular events during treatment with dasatinib typically affect
the pulmonary vessels, often determining a clinical presentation
TABLE 1 | Currently available ABL-inhibiting TKIs, their known
cardiovascular-associated toxicity, and the possible underlying mechanisms.
TKI gen Drug Cardiovascular toxicity Involved mechanisms










levels (in vitro and in vivo),
inhibition of endothelial cell
proliferation, increased glucose
levels, glomerular impairment,
mast cell disruption (impaired
tissue repair)





2nd Bosutinib Potentially none NA




similar to nilotinib. Dose
dependent.
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of pulmonary arterial hypertension (PAH). Due to the complex
diagnostic means by which PAH is diagnosed, data from the most
important dasatinib trials do not include PAH evaluation and
measurement. Dasatinib-induced PAH mechanisms still remain
unclear, but there are some hints that chronic exposure to
dasatinib may attenuate hypoxic pulmonary vasoconstriction
responses and thus increase susceptibility to PAH. Despite this
initial thinking, it seems that this mechanism is independent
of Src-inhibition (Guignabert et al., 2016; Özgür Yurttaş and
Eşkazan, 2018).
In 2012, the French Pulmonary Hypertension Registry
reported nine patients with PAH related to dasatinib. From
the result of the Registry, it was estimated that PAH happens
in at least 0.45% of individuals who are chronically exposed
to dasatinib. In those cases, the withdrawal from the drug
determined significant improvements of the subjective and
objective presentation (Montani et al., 2012).
Pleural effusion, which is not actually a cardiac or vascular
toxicity, is, however, an adverse event that comes into
differential diagnosis with cardiac impairment. The drug-
related pathological mechanism is known to be an off-target
Src kinase inhibitor, with the consequence of abnormal
pleural fluid retention (Cortes et al., 2017). Another possible
mechanism involved in pleural effusion determination during
dasatinib assumption is dasatinib-triggered autoimmunity
(de Lavallade et al., 2008).
Nilotinib
Nilotinib exerts a much more potent imatinib-like ABL
inhibition, thus resulting in better molecular responses with the
possible cost of a worse safety profile. In terms of CV toxicity,
nilotinib triggers a prothrombotic state, increasing thrombosis
mediators such as P-selectin and potentiating the PAR-1-
mediated alpha granule release. Furthermore, exams performed
on CML patients’ peripheral blood revealed increased ex vivo
platelet adhesive function, increased soluble P-selectin in these
patients’ plasma, and increased levels of sICAM-1, sVCAM-1,
TNF-alpha, IL-6 as well, along with the increase in endogenous
thrombin potential levels in vivo, despite being on daily low-dose
aspirin (Alhawiti et al., 2016; Bocchia et al., 2016; Hadzijusufovic
et al., 2017).
Bosutinib
The bosutinib cardiac and vascular risk profile is probably
comparable to that of Imatinib. Despite the already low CV
risk added by this TKI, it has to be highlighted that data on
bosutinib cardiac and vascular toxicity contain the bias that the
trials leading to its approval were performed on at least third-
line CML patients, often heavily pretreated with other TKIs
with the over mentioned CV toxicity. Moreover, bosutinib real-
life data come from at least second-line CML patients and in
second-line patients frequently in presence of a cardiovascular
disease or of a moderate-to-high cardiovascular risk, which is
commonly the reason that they are not suitable to second-line
dasatinib, nilotinib, or ponatinib (Gambacorti-Passerini et al.,
2014; Brümmendorf et al., 2016; Cortes et al., 2016).
Ponatinib
Due to its high affinity to the ABL ATP-binding site, ponatinib
is probably the most potent BCR-ABL-inhibiting drug in the
treatment of CML. The pivotal PACE trial initially reported a
high rate of cardiovascular severe adverse events, and the drug
was temporarily suspended from commerce by the United States
FDA and reintroduced when analysis of CV risk factors in
patients who developed CV complications was completed and
it was demonstrated that those occurred mostly in patients with
pre-ponatinib high CV risk (Valent et al., 2017).
The 5-year follow-up report of the pivotal phase 2 Ponatinib
Ph1 ALL and CML Evaluation (PACE) trial revealed cumulative
rates of treatment-emergent arterial obstructive events of 31% (84
events) in the chronic phase CML (CP-CML) subgroup. Exposure
adjusted events accounted for 14.1 events per 100 patients per
year. In the evaluation of these data, we have to take trial-enrolled
patients with CP-CML with intolerance or resistance to dasatinib
or nilotinib, and the derived cohort of 270 CP-CML patients
took ponatinib as at least the third line of TKI therapy in 57%
of the cases. It is strongly accepted nowadays that CV toxicity
of ponatinib is dose-dependent. It is notable that treatment-
emergent arterial obstructive events occurred with lower rates in
the reduced dosage group; in particular, the ponatinib dose at
initial onset of the event was 45 mg in 42% of patients, 30 mg
in 24%, and 15 mg in 26%. Initial onset of the first event occurred
in the post-study follow-up in 7% of cases.
Moreover, risk factors for the development of serious arterial
obstructive events were identified in the study: traditional CV
risk factors, such as hypertension, hypercholesterolemia, diabetes,
obesity, and a history of ischemic and non-ischemic cardiac
disease. The gradual increase of the number of conventional
and non-conventional risk factors determines the increment of
the rate of arterial thrombotic events in the lower-level analysis,
increasing from 0 to 1 and from 1 to 2 or more risk factors
(Cortes et al., 2018).
In a recent report we published, the series of five patients
with CML who harbored high global cardiovascular risk or had
already experienced heart disease were reported to develop no
CV adverse events after a median follow-up time of 34 months,
assuming ponatinib at the lowest effective dose, when other
therapies were not possible or available (Santoro et al., 2019).
PREVENTIVE STRATEGIES
The first step on the path to achieving an efficient cardiovascular
prevention strategy is the correct patient evaluation and risk
classification. The very important and sometimes problematic
choice of one TKI instead of another has to be guided by disease
features and patient characteristics as well, and it has to comply
with the established purposes of therapy that come from that
first assessment.
Pre-TKI cardiovascular risk assessment is probably one of
the turning points and an important unmet clinical need in
the field of CML cardio-oncology. One issue of significant
relevance is which risk score is better to obtain affordable baseline
CML patient evaluation in order to eventually exclude first-line
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nilotinib or ponatinib. There is no evidence that high CV-risk
patients have to avoid dasatinib, even if the risk of PAH is
known and present.
The extensively used SCORE charts have the pros of being
targeted and standardized on populations from different areas,
not limited to United States data, but they were validated to
estimate 10-year risk of fatal events only and thus may be
inappropriate for evaluating the global CV risk (Breccia et al.,
2015). On the other hand, the Framingham risk score predicts the
risk of developing a cardiovascular disease during the following
10 years but does not take into account PAOD, a commonly
reported nilotinib and ponatinib vascular adverse event, as a
possible outcome (D’Agostino et al., 2008).
Targeting the modifiable CV risk factors after CML
diagnosis is undoubtedly the preferred strategy, despite the
choice upfront of TKI.
Although low-dose aspirin prevents recurrent CV events
in patients with previous diagnosis of CV disease, its role
in primary prevention in patients with no CVD is still
under consideration. Meta-analyses have revealed that primary
prevention with low-dose aminosalicylic acid guarantees a
10–13% relative risk reduction in serious CV events, at the
cost of a risk of intracranial and gastrointestinal hemorrhage
(Capodanno and Angiolillo, 2016).
Even if relative contraindications are suggested by
international recommendations for the management of CML,
absolute contraindications based on cardiovascular risk are hard
to accept for patients with multiple types of intolerance or
resistance due to point mutations that require ponatinib as the
only possible treatment. Real-life data support the use of reduced
doses of second and third generation TKIs to maintain optimal
responses in patients initially treated with a full dose, with the
aim of minimizing dose-dependent cardiovascular toxicity.
Upfront dose reduction is still a taboo theme, even if
pharmacokinetic analysis has indicated that ponatinib dose
reduction to 15 mg a day upfront in CP-CML may confer
advantages in terms of safety, while maintaining its efficacy
(Molica et al., 2019).
Cardio-oncology units are available nowadays to refine
the cardiological, basal, and follow-up evaluation of patients
with hematological neoplasms, eligible for TKI therapies. Basal
evaluation is preferable in all CML patients, despite the
chosen first-line TKI. A cardiovascular risk stratification and
multidisciplinary approach are essential steps to minimize the
global CV risk for the patient and therefore optimize the
possibility of fully treating the disease. Cardio-oncology follow-
up schedules are still not standardized.
CONCLUSION AND PERSPECTIVES
Adverse CVAEs are still a major issue in CML treatment,
becoming possible comorbidities in the landscape of an expected
very favorable long-term outcome.
The availability of an appropriate CV risk score for baseline
evaluation of CML patients eligible for TKI treatment is
an unmet clinical need. The validation of a score that
estimates the 10-year probability of developing fatal and non-
fatal cardiovascular disease, including myocardial ischemia,
cerebrovascular ischemia, peripheral artery obstructive disease,
and cardiac death, is strongly desired.
Cardio-oncology unit referral at diagnosis and during the
recommended follow-up is considered useful and advantageous
in the global management of patients on nilotinib or dasatinib
but is suggested also in CML patients assuming other TKIs.
Optimizing modifiable CV risk factors through lifestyle
modification and eventual prescription of primary prophylactic
drugs is the preferred strategy to be applied upon CML
diagnosis, despite the TKI chosen. The use of low-dose aspirin
for primary prevention may reduce the pre-TKI CV risk in
selected patients.
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